Abstract 468P
Background
Third-generation regimens with chemoradiotherapy has been established as one of a standard treatment in the phase III study WJTOG0105 even 10 years after starting treatment. We conducted an additional analysis by the histological type (Non-squamous [Non-Sq] vs. Squamous [Sq]) to examine differences of efficacy and patterns of initial failure.
Methods
Patients received the following treatments: MVP, mitomycin (8 mg/m2 on day 1, 29), vindesine (3 mg/m2 on day 1, 8, 29, 36), and cisplatin (80 mg/m2 on day 1, 29) with concurrent TRT (60 Gy), followed by 2 courses of MVP; IC, weekly irinotecan (20 mg/m2)/carboplatin (AUC 2) for 6 weeks with concurrent TRT (60 Gy), followed by 2 courses of irinotecan (50 mg/m2)/carboplatin (AUC 5); PC, weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) for 6 weeks with concurrent TRT (60 Gy), followed by 2 courses of paclitaxel (200 mg/m2)/carboplatin (AUC 5). Overall survival (OS), progression free survival (PFS), and patterns of initial failure were compared by the histological type.
Results
From September 2001 to September 2005, 440 patients (arm A, n = 146; arm B arm, n = 147; arm C, n = 147) were enrolled. The median follow-up time 140 months. The median OS and PFS were 23.5, 8.3 months in Non-Sq and 19.7, 8.3 months in Sq. The efficacy of PC and IC was compared with MVP in each histological type. For Non-Sq, the median OS and PFS were 25.1, 8.3 months in PC and 20.3, 8.3 months in IC and 25.2, 8.4 months in MVP. For Sq, the median OS and PFS were 20.5, 9.9 months in PC and 17.1, 7.8 months in IC and 19.4, 8.3 months in MVP. There was no statistically significant difference in OS and PFS between PC, IC and MVP in each histological type. In the patterns of initial failure, out-field recurrence rate in Non-Sq (51.1%) was higher than Sq (26.1%). Furthermore, the patterns of initial failure were similar between PC, IC and MVP.
Conclusions
Weekly PC with concurrent TRT showed similar efficacy to MVP with concurrent TRT, with no correlation to the histological type in 10-years follow-up with WJTOG0105. In the pattern of initiated failure, out-field recurrence in Non-Sq was tend to be higher than in Sq.
Clinical trial identification
Clinical trial information: 000030811.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
West Japan Oncology Group (WJOG).
Disclosure
M. Tsuboi: Honoraria (institution): Bristol-Myers Squibb. M. Satouchi: Honoraria (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. D. Fujimoto: Honoraria (self): Bristol-Myers Squibb. T. Hirashima: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. N. Yamamoto: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. K. Nakagawa: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract